S&P 500 7,459.94 â–ŧ 73.83 (-0.98%) DOW 52,169.10 â–ŧ 383.87 (-0.73%) NASDAQ 25,535.42 â–ŧ 346.53 (-1.34%) US Markets Closed â€ĸ 11:57 PM ET

UPB

Upstream Bio, Inc.

Price Chart
Latest Quote

$7.01

-0.22 (-3.04%)
Current Price
Previous Close $7.23
Open $7.08
Day High $7.30
Day Low $6.90
Volume 348,290
Fetched: 2026-07-18T03:57:44
Stock Information
Shares Outstanding 54.42M
Total Debt $1.11M
Cash Equivalents $294.58M
Revenue $3.32M
Net Income $-156.76M
Sector Healthcare
Industry Biotechnology
Market Cap $381.48M
EPS (TTM) $-2.90
Exchange NMS
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$88.02M
Sales$3.32M
Income$-156.76M
Book/sh$5.59
Cash/sh$5.41
Employees75
Financial Ratios
Quick Ratio21.74
Current Ratio23.14
Debt/Eq0.37
Returns & Margins
ROA-27.76%
ROE-41.83%
Gross Margin100.00%
Operating Margin-4218.09%
Ownership
Insider Ownership14.88%
Institutional Ownership88.32%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-2.43
P/S114.84
P/B1.25
Analyst Data
Recommendationnone
Target Price$38.25
Technical Indicators
SMA20$7.07
SMA50$7.53
SMA200$16.59
RSI54.81
ATR0.4512
Shares Float40.53M
Short Float11.63%
Short Ratio5.65
Rel Volume0.62
Performance History
Week-6.91%
Month+18.41%
Quarter-30.59%
6 Months-78.30%
YTD-74.10%
Year-35.81%
10 Years-68.14%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-07-17 $7.01 354,220
2026-07-16 $7.23 561,200
2026-07-15 $7.27 332,100
2026-07-14 $7.14 344,700
2026-07-13 $7.28 266,100
2026-07-10 $7.53 341,700
2026-07-09 $7.81 467,500
2026-07-08 $7.98 635,100
2026-07-07 $7.86 809,500
2026-07-06 $7.40 357,000
2026-07-02 $7.51 363,200
2026-07-01 $7.28 561,000
2026-06-30 $6.92 557,800
2026-06-29 $6.93 662,700
2026-06-26 $6.75 1,311,200
2026-06-25 $6.36 469,900
2026-06-24 $6.35 654,600
2026-06-23 $6.32 623,900
2026-06-22 $6.30 849,200
2026-06-18 $6.25 829,700
About Upstream Bio, Inc.

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Total Revenue $2,854,000 $2,370,000 $2,380,000 $1,212,000
Operating Revenue $2,854,000 $2,370,000 $2,380,000 $1,212,000
Expenses
Total Expenses $163,215,000 $80,134,000 $42,494,000 $25,121,000
Other Income Expense $-15,000 $2,835,000 $15,412,000 $-164,000
Other Non Operating Income Expenses $-15,000 $2,835,000 $15,412,000 $-164,000
Net Non Operating Interest Income Expense $16,933,000 $12,123,000 $4,165,000 $205,000
Operating Expense $163,215,000 $80,134,000 $42,494,000 $25,121,000
General And Administrative Expense $26,409,000 $17,168,000 $10,695,000 $6,464,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Net Interest Income $16,933,000 $12,123,000 $4,165,000 $205,000
Interest Income $16,933,000 $12,123,000 $4,165,000 $205,000
Normalized Income $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Net Income From Continuing And Discontinued Operation $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Total Operating Income As Reported $-160,361,000 $-77,764,000 $-40,114,000 $-23,909,000
Net Income Common Stockholders $-143,443,000 $-76,395,000 $-38,255,000 $-23,868,000
Net Income $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Net Income Including Noncontrolling Interests $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Net Income Continuous Operations $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Pretax Income $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Interest Income Non Operating $16,933,000 $12,123,000 $4,165,000 $205,000
Operating Income $-160,361,000 $-77,764,000 $-40,114,000 $-23,909,000
Per Share
Diluted EPS $-2.64 $-1.17 $-1.05 $-0.66
Basic EPS $-2.64 $-1.17 $-1.05 $-0.66
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-160,173,000 $-77,675,000 $-40,054,000 $-23,902,000
Reconciled Depreciation $188,000 $89,000 $60,000 $7,000
EBITDA (Bullshit earnings) $-160,173,000 $-77,675,000 $-40,054,000 $-23,902,000
EBIT $-160,361,000 $-77,764,000 $-40,114,000 $-23,909,000
Diluted Average Shares $54,237,750 $53,603,398 $36,323,322 $36,323,322
Basic Average Shares $54,237,750 $53,603,398 $36,323,322 $36,323,322
Diluted NI Availto Com Stockholders $-143,443,000 $-76,395,000 $-38,255,000 $-23,868,000
Research And Development $136,806,000 $62,966,000 $31,799,000 $18,657,000
Selling General And Administration $26,409,000 $17,168,000 $10,695,000 $6,464,000
Other Gand A $11,221,000 $6,326,000 $4,343,000 $2,728,000
Salaries And Wages $15,188,000 $10,842,000 $6,352,000 $3,736,000
Preferred Stock Dividends - $13,589,000 $17,718,000 -
Fetched: 2026-07-17
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Total Assets $353,772,000 $481,719,000 $117,198,000 $18,478,000
Total Non Current Assets $1,975,000 $2,559,000 $202,000 $171,000
Other Non Current Assets $194,000 $194,000 - $7,000
Current Assets $351,797,000 $479,160,000 $116,996,000 $18,307,000
Other Current Assets $727,000 $494,000 $370,000 $233,000
Prepaid Assets $7,240,000 $7,035,000 $6,580,000 $611,000
Receivables $2,321,000 $1,180,000 $236,000 $412,000
Accrued Interest Receivable $1,653,000 $567,000 $138,000 $0
Accounts Receivable $668,000 $613,000 $98,000 $412,000
Cash Cash Equivalents And Short Term Investments $341,509,000 $470,451,000 $109,810,000 $17,051,000
Cash And Cash Equivalents $101,578,000 $325,892,000 $25,833,000 $17,051,000
Debt
Total Debt $1,269,000 $1,834,000 $45,000 $94,000
Long Term Debt And Capital Lease Obligation $549,000 $1,130,000 $0 $7,000
Current Debt And Capital Lease Obligation $720,000 $704,000 $45,000 $87,000
Liabilities
Total Liabilities Net Minority Interest $14,001,000 $11,867,000 $240,324,000 $124,633,000
Total Non Current Liabilities Net Minority Interest $549,000 $1,130,000 $233,809,000 $119,777,000
Current Liabilities $13,452,000 $10,737,000 $6,515,000 $4,856,000
Payables And Accrued Expenses $8,540,000 $7,336,000 $4,302,000 $3,876,000
Payables $2,726,000 $4,041,000 $1,990,000 $712,000
Accounts Payable $2,726,000 $4,041,000 $1,990,000 $712,000
Equity
Common Stock Equity $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Total Equity Gross Minority Interest $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Stockholders Equity $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Gains Losses Not Affecting Retained Earnings $530,000 $-25,000 $21,000 $0
Other Equity Adjustments $530,000 $-25,000 $21,000 -
Retained Earnings $-334,223,000 $-190,780,000 $-127,974,000 $-107,437,000
Preferred Securities Outside Stock Equity - $0 $233,809,000 $119,770,000
Other
Ordinary Shares Number $54,237,750 $53,603,398 $51,341,695 $51,341,695
Share Issued $54,237,750 $53,603,398 $51,341,695 $51,341,695
Tangible Book Value $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Invested Capital $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Working Capital $338,345,000 $468,423,000 $110,481,000 $13,451,000
Capital Lease Obligations $1,269,000 $1,834,000 $45,000 $94,000
Total Capitalization $339,771,000 $469,852,000 $-123,126,000 $-106,155,000
Additional Paid In Capital $673,410,000 $660,604,000 $4,824,000 $1,279,000
Capital Stock $54,000 $53,000 $3,000 $3,000
Common Stock $54,000 $53,000 $3,000 $3,000
Preferred Stock $0 $0 $0 -
Long Term Capital Lease Obligation $549,000 $1,130,000 $0 $7,000
Current Capital Lease Obligation $720,000 $704,000 $45,000 $87,000
Pensionand Other Post Retirement Benefit Plans Current $4,192,000 $2,697,000 $2,168,000 $893,000
Current Accrued Expenses $5,814,000 $3,295,000 $2,312,000 $3,164,000
Net PPE $1,781,000 $2,365,000 $202,000 $164,000
Accumulated Depreciation $-344,000 $-156,000 $-67,000 $-7,000
Gross PPE $2,125,000 $2,521,000 $269,000 $171,000
Leases $87,000 $71,000 $27,000 $18,000
Other Properties $1,222,000 $1,783,000 $43,000 $89,000
Machinery Furniture Equipment $816,000 $667,000 $199,000 $22,000
Properties $0 $0 $0 $0
Other Short Term Investments $239,931,000 $144,559,000 $83,977,000 $0
Construction In Progress - - $0 $42,000
Fetched: 2026-07-17
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-133,440,000 $-59,683,000 $-38,070,000 $-19,103,000
Operating Activities
Operating Cash Flow $-133,275,000 $-59,172,000 $-37,926,000 $-19,021,000
Cash Flow From Continuing Operating Activities $-133,275,000 $-59,172,000 $-37,926,000 $-19,021,000
Investing Activities
Capital Expenditure $-165,000 $-511,000 $-144,000 $-82,000
Investing Cash Flow $-93,480,000 $-59,485,000 $-82,842,000 $-82,000
Cash Flow From Continuing Investing Activities $-93,480,000 $-59,485,000 $-82,842,000 $-82,000
Financing Activities
Issuance Of Capital Stock $0 $422,647,000 $129,432,000 $10,000,000
Financing Cash Flow $2,441,000 $418,910,000 $129,550,000 $9,963,000
Cash Flow From Continuing Financing Activities $2,441,000 $418,910,000 $129,550,000 $9,963,000
Net Other Financing Charges $-34,000 $-3,896,000 - $-37,000
Net Preferred Stock Issuance $0 $149,924,000 $129,432,000 $10,000,000
Preferred Stock Issuance $0 $149,924,000 $129,432,000 $10,000,000
Net Common Stock Issuance $0 $272,723,000 $0 -
Common Stock Issuance $0 $272,723,000 $0 -
Other
End Cash Position $101,772,000 $326,086,000 $25,833,000 $17,051,000
Beginning Cash Position $326,086,000 $25,833,000 $17,051,000 $26,191,000
Changes In Cash $-224,314,000 $300,253,000 $8,782,000 $-9,140,000
Proceeds From Stock Option Exercised $2,475,000 $159,000 $118,000 $0
Net Investment Purchase And Sale $-93,315,000 $-58,974,000 $-82,698,000 $0
Sale Of Investment $292,563,000 $231,635,000 $46,292,000 $0
Purchase Of Investment $-385,878,000 $-290,609,000 $-128,990,000 $0
Net PPE Purchase And Sale $-165,000 $-511,000 $-144,000 $-82,000
Purchase Of PPE $-165,000 $-511,000 $-144,000 $-82,000
Change In Working Capital $589,000 $1,873,000 $-4,305,000 $3,412,000
Change In Other Current Liabilities $-565,000 $-133,000 $-82,000 $-67,000
Change In Payables And Accrued Expense $2,733,000 $3,529,000 $1,700,000 $4,483,000
Change In Accrued Expense $4,014,000 $1,512,000 $422,000 $4,021,000
Change In Payable $-1,281,000 $2,017,000 $1,278,000 $462,000
Change In Account Payable $-1,281,000 $2,017,000 $1,278,000 $462,000
Change In Prepaid Assets $-1,524,000 $-1,008,000 $-6,237,000 $-585,000
Change In Receivables $-55,000 $-515,000 $314,000 $-412,000
Changes In Account Receivables $-55,000 $-515,000 $314,000 $-412,000
Other Non Cash Items $561,000 $-2,677,000 $-15,311,000 $149,000
Stock Based Compensation $10,332,000 $6,004,000 $3,427,000 $1,279,000
Amortization Of Securities $-1,502,000 $-1,655,000 $-1,260,000 $0
Depreciation Amortization Depletion $188,000 $89,000 $60,000 $7,000
Depreciation And Amortization $188,000 $89,000 $60,000 $7,000
Net Income From Continuing Operations $-143,443,000 $-62,806,000 $-20,537,000 $-23,868,000
Change In Other Current Assets - - $0 $-7,000
Fetched: 2026-07-17